IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: Irreversible inhibition of the differentiation program activated by RANKL

Blood

Volumn 102, Issue 3, 2003, Pages 1078-1086

  Moreno, Jose L ^b   Kaczmarek, Michele ^b   Keegan, Achsah D ^b   Tondravi, Mehrdad ^a  

^a HOLLAND LABORATORY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; STAT6 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; GENE EXPRESSION REGULATION; GIANT CELL; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0042744757     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3437     Document Type: Article

References (42)

1. Miyamoto T, Ohneda O, Arai F, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood. 2001;98:2544-2554.
2. McNally AK, Anderson JM. Interleukin-4 induces foreign body giant cells from human monocytes/macrophages: differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells. Am J Pathol. 1995;147:1487-1499.
3. Anderson JM. Multinucleated giant cells. Curr Opin Hematol. 2000;7:40-47.
4. Guironnet G, Dezutter-Dambuyant C, Vincent C, Bechetoille N, Schmitt D, Peguet-Navarro J. Antagonistic effects of IL-4 and TGF-β1 on Langerhans cell-related antigen expression by human monocytes. J Leukoc Biol. 2002;71:845-853.
5. Wei S, Wang MW, Teitelbaum SL, Ross FP. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signaling. J Biol Chem. 2002;277:6622-6630.
6. Watanabe K, Tanaka Y, Morimoto I, et al. Interleukin-4 as a potent inhibitor of bone resorption. Biochem Biophys Res Commun. 1990;172:1035-1041.
7. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J Clin Invest. 2001;107:1375-1385.
8. Lacey DL, Erdmann JM. Teitelbaum SL, Tan HL. Ohara J, Shioi A. Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology. 1995;136:2367-2376.
9. Suk K, Somers SD, Erickson KL. Regulation of murine macrophage function by IL-4: IL-4 and IFN-γ differentially regulate macrophage tumoricidal activation. Immunology. 1993;80:617-624.
10. Allen JE, Maizels RM. Th1-Th2: reliable paradigm or dangerous dogma? Immunol Today. 1997;18: 387-392.
11. Nelms K, Keegan AD, Zamorano J, Ryan JJ. Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999; 17:701-738.
12. Jansen JH, Fibbe WE, Willemze R, Kluin-Nelemans JC. Interleukin-4: a regulatory protein. Blut. 1990;60:269-274.
13. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 1993;362:245-248.
14. Yeatman CF, Jacobs-Helber SM, Mirmonsef P, et al. Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med. 2000;192:1093-1103.
15. Shioi A, Teitelbaum SL, Ross FP, et al. Interleukin 4 inhibits murine osteoclast formation in vitro. J Cell Biochem. 1991;47:272-277.
16. Nakano Y, Watanabe K, Morimoto I, et al. Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res. 1994;9: 1533-1539.
17. Riancho JA, Zarrabeitia MT, Mundy GR, Yoneda T, Gonzalez-Macias J. Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells. J Bone Miner Res. 1993;8:1337-1344.
18. Kasono K, Sato K, Sato Y, Tsushima T, Shizume K, Demura H. Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture. Bone Miner. 1993;21:179-188.
19. Okada Y, Morimoto I, Ura K, et al. Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice. Bone. 1998;22:361-365.
20. Roodman GD. Advances in bone biology: the osteoclast. Endocrinol Rev. 1996;17:308-332.
21. Riancho JA, Zarrabeitia MT. Gonzalez-Macias J. Interleukin-4 modulates osteoclast differentiation and inhibits the formation of resorption pits in mouse osteoclast cultures. Biochem Biophys Res Commun. 1993;196:678-685.
22. + in murine osteoclasts. J Biol Chem. 1994;269:13817-13824.
23. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597-3602.
24. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795-823.
25. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179.
26. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93: 165-176.
27. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272:25190-25194.
28. Zamorano J, Mora AL, Boothby M, Keegan AD. NF-κB activation plays an important role in the IL-4-induced protection from apoptosis. Int Immunol. 2001;13:1479-1487.
29. Tondravi MM, McKercher SR, Anderson K, et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature. 1997;386:81-84.
30. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000;191:275-286.
31. Akatsu T, Tamura T, Takahashi N, et al. Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J Bone Miner Res. 1992;7:1297-1306.
32. Tamura T, Takahashi N, Akatsu T, et al. New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro. J Bone Miner Res. 1993;8:953-960.
33. Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor B (RANK) receptors. J Exp Med. 1999;190:1741-1754.
34. Xing L, Bushnell TP, Carlson L, et al. NF-κB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor f. J Bone Miner Res. 2002;7:1200-1210.
35. Lewis DB, Liggitt HD, Effmann EL, et al. Osteoporosis induced in mice by overproduction of interleukin 4. Proc Natl Acad Sci U S A. 1993;90: 11618-11622.
36. McInnes A, Rennick DM. Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells. J Exp Med. 1988;167:598-611.
37. Ogata N, Chikazu D, Kubota N, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest. 2000; 105:935-943.
38. Akune T, Ogata N, Hoshi K, et al. Mice lacking insulin receptor substrate-2 exhibit osteopenis with decreased bone formation and increased osteoblast mediated osteoclastogenesis. J Bone Miner Res. 2001;16(suppl 1):161.
39. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
40. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000;97:1566-1571.
41. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13;2412-2424.
42. Bennett BL, Cruz R, Lacson RG, Manning AM. Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-κB. J Biol Chem. 1997;272:10212-10219.